02:00 Thu 10 Sep 2020
Destiny Pharma PLC - Notice of Results
("Destiny Pharma" or "the Company")
Notice of Interim Results
A webcast for analysts will take place at
-END-
For further information, please contact:
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
Mary Clark, Shabnam Bashir, Manel Mateus
Tel: +44 (0) 203 174 1789
Email: DestinyPharma@optimumcomms.com
finnCap Ltd (Nominated Advisor Joint Broker)
Geoff Nash /Kate Bannatyne, Corporate Finance
+44 (0)20 7220 0500
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0) 203 705 9330
About Destiny Pharma
Destiny Pharma is an established, clinical stage, innovative biotechnology company focused on the development of novel medicines from its XF Platform that represent a new approach to the treatment of infectious disease. The company's lead programme is undergoing a Phase 2b clinical trial and is targeting the prevention of post-surgical hospital infections including MRSA. The XF drug candidates are being developed for the prevention and treatment of life-threatening infections caused by antibiotic‑resistant bacteria, often referred to as "superbugs". Tackling anti-microbial resistance has become a global imperative recognised by the
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE